# Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes

> **NCT07172269** · NA · COMPLETED · sponsor: **Mais Qais Hbeeb** · enrollment: 58 (actual)

## Conditions studied

- Diabete Mellitus
- Type 2 Diabetes
- Obesity Type 2 Diabetes Mellitus
- Dyslipidemia in Patients With Diabetes Mellitus
- Insulin Resistance

## Interventions

- **DRUG:** Sitagliptin + Metformin
- **DIETARY_SUPPLEMENT:** mangosteen supplement
- **BEHAVIORAL:** Lifestyle Management

## Key facts

- **NCT ID:** NCT07172269
- **Lead sponsor:** Mais Qais Hbeeb
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-15
- **Primary completion:** 2025-05-26
- **Final completion:** 2025-05-26
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07172269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07172269, "Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07172269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*